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The First World Lung Disease Summit took place in Lisbon over two days in November 
2013. This inaugural meeting, of what is hoped to be a long-running annual series, 
brought together experts in respiratory medicine to explore many of the issues and 
challenges faced by clinicians when managing lung diseases, particularly asthma and 
COPD. The aim of the series is to present and discuss innovative science through a 
scientifically balanced program, and to explore how recent developments can inform 
clinical practice and improve patient care. The program for the inaugural meeting 
emphasized ongoing work in basic, clinical, and translational science as it evolves to 
bring about a more complete understanding of the pathology of asthma and COPD. 
The overall goal of the meeting was to provide delegates with insights into treatment 
approaches, with the aim of improving patient outcomes. This was an interactive 
symposium with opportunities for the delegates to express their opinions and practices 
and to learn how their peers manage lung diseases. The meeting program comprised 
three modules, each with four presenters, and explored three specific aspects of lung 
disease: the diagnosis and assessment of COPD, the patient perspective, and exacerba-
tions in COPD. The presenters of each module have summarized their presentations 
in the three articles that comprise this special issue.
The first module covered the challenges associated with obtaining an accurate diag-
nosis and assessment of COPD, which are necessary to inform subsequent management 
of the disease. As summarized by Lange et al, this session covered the differentiation 
and overlap of COPD and asthma, and the use of diagnostic procedures beyond the 
standard spirometric measurements to ensure a sound diagnosis. The heterogeneity 
of COPD and the search to identify subpopulations, or phenotypes, that share certain 
disease characteristics predicting response to specific treatment strategies were also 
discussed. As reported by Jones et al, in module 2 the speakers considered the patient’s 
perspective of COPD. This included discussion of the tools available to assess disease 
impact on a patient’s daily life, the role of physical activity in COPD (both in terms 
of prognosis and rehabilitation), and the influence of comorbidities. Treatment-related 
factors such as choice of inhaler device and combination therapies for COPD were 
also covered. Finally, in module 3 the focus of the presentations moved to exacerba-
tions in COPD. As Pavord et al report, this included the impact of exacerbations, the 
heterogeneity of the factors triggering them, and the complexity of identifying the most 
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appropriate therapy. The audience heard that, as in COPD 
more generally, patterns of exacerbations are emerging and 
that the search is on for common factors, including biomark-
ers, to guide treatment decisions.
During the First World Lung Disease Summit, we were 
given an insight into the ideas and thoughts guiding current 
research in respiratory medicine, allowing us a glimpse of 
what may come. The aim of this special issue is to share that 
knowledge and insight, in order to inform and inspire a wider 
audience with an interest in respiratory medicine.
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